10-K/A: Allakos Inc. Files Amendment to 10-K Report to Include Omitted Information on Directors, Executive Compensation, and Governance

Allakos Inc. filed an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive compensation, and corporate governance.

Summary

• Allakos Inc. is filing Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, to provide additional information required by Part III of Form 10-K.
• The original 10-K omitted this information in reliance on General Instruction G(3) of Form 10-K because a definitive proxy statement containing such information will not be filed within 120 days after the end of December 31, 2024.
• This amendment does not change the previously reported financial statements or any other disclosure contained in Part I or Part II of the original 10-K.
• The amendment includes new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
• The aggregate market value of the common stock held by non-affiliates of the Registrant based on the closing price of the Registrant's Common Stock on the Nasdaq Global Select Market as of June 30, 2024, was $81.7 million.
• As of March 5, 2025, the number of shares of Registrant's Common Stock outstanding was 90,203,245.
• The document details information about the company's directors, executive officers, corporate governance practices, executive compensation, security ownership, and related party transactions.
• The company's executive compensation program seeks to incentivize and reward strong corporate performance and is structured using three primary elements: base salary, annual cash incentives, and long-term equity incentives.
• The peer group utilized for the 2024 compensation analysis included companies such as Annexon, Inc., Gossamer Bio, Inc., and Omeros Corporation.
• The base salaries for NEOs were adjusted in 2024, with Baird Radford receiving a 3% increase, while Robert Alexander and Adam Tomasi remained the same.
• Annual cash incentive awards were earned at 100% of each NEO's applicable target bonus, except for Mr. Radford who earned 109% of his target bonus.
• Long-term equity incentives in the form of stock options were granted to all NEOs in 2024.
• The company maintains a 401(k) retirement savings plan for the benefit of its employees, including NEOs, with a matching contribution.
• The document also includes information on director compensation, with each nonemployee director granted an option to purchase 41,000 shares of common stock in May 2024.
• Ernst & Young LLP charged $1,115,975 in audit fees for 2024.
• Robert Alexander, as CEO, and H. Baird Radford, as CFO, certified the accuracy of the amended report.

Sentiment

Score: 6

Explanation: The document is primarily factual and descriptive, with a neutral tone. The cancellation of the lirentelimab program is a negative, but the company is taking steps to improve transparency and align executive compensation with stockholder interests.

Positives

• The company is providing more transparent disclosure about its executive compensation program.
• The executive compensation program is designed to align the interests of executives with those of stockholders.
• The company maintains a compensation clawback policy.
• The company has an independent Compensation Committee and uses an independent compensation consultant.
• The company offers a 401(k) plan with employer matching contributions.

Negatives

• The company halted development of lirentelimab in January 2024, leading to the cancellation of PSUs for NEOs.
• The company incurred a net loss of $115,818,000 in 2024.
• The aggregate market value of the common stock held by non-affiliates of the Registrant based on the closing price of the Registrant's Common Stock on the Nasdaq Global Select Market as of June 30, 2024, was $81.7 million.

Risks

• The biopharmaceutical industry is characterized by a very long product development cycle, including a lengthy research and development period and a rigorous approval phase involving clinical studies and governmental regulatory and marketing approval.
• The company competes for executive talent with many public companies that are larger and more established or that possess greater resources.
• The company's stock price performance is likely to fluctuate based on its operational performance.

Future Outlook

The document does not contain specific forward-looking statements beyond the standard business operations and compensation practices.

Industry Context

The document highlights the competitive landscape for executive talent in the biopharmaceutical industry, noting that Allakos competes with larger, more established companies and smaller private companies.

Comparison to Industry Standards

• The Compensation Committee uses a peer group of publicly traded biopharmaceutical and biotechnology companies to benchmark executive compensation.
• The peer group includes companies such as Annexon, Inc., Gossamer Bio, Inc., and Omeros Corporation.
• The company aims to provide compensation that is competitive with the 50th to 75th percentile of its peer group.
• The company's outside director compensation policy is designed to provide reasonable compensation that is commensurate with their contributions and appropriately aligned with its peers.

Stakeholder Impact

• The executive compensation program is designed to align the interests of executives with those of stockholders.
• The company's compensation clawback policy protects stockholders in the event of certain financial statement restatements.
• The company's 401(k) plan provides employees with an opportunity to save for retirement on a tax-advantaged basis.

Key Dates

Keywords

executive compensation, corporate governance, directors, NEOs, stock options, equity incentives, Form 10-K, Allakos, audit fees, biopharmaceutical